Search inside of Supercourse and lectures in HTML and PPT format
 |
 |
 |
front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39 |40 |41 |42 |43 |44 |45 |46 |47 |48 |49 |50 |51 |52 |53 |54 |55|56 |57 |58 |59 |60 |61 |62 |review |
 As shown there is remarkable consistency for the mean number of A1months experienced at the time of first development of complications both across duration and across of type of complication, PR being proliferative retinopathy, MA microalbuminuria, ON overt nephropathy, and NE neuropathy. Approximately 1000 A1months is the key degree of glycemic exposure which relates to the first manifestation of complications. |
As shown there is remarkable consistency for the mean number of A1months experienced at the time of first development of complications both across duration and across of type of complication, PR being proliferative retinopathy, MA microalbuminuria, ON overt nephropathy, and NE neuropathy. Approximately 1000 A1months is the key degree of glycemic exposure which relates to the first manifestation of complications. |